Lyons and Clermont-Ferrand (France), February 1st, 2010 - The biopharmaceutical company Imaxio has announced the installation of the new Illumina Ultra High Throughput genotyping platform in its enlarged and refurbished laboratories in Clermont-Ferrand. This technology will allow Imaxio’s customers and partners to access a new platform for ultra high throughput genotyping studies which will perfectly fit with the genomic DNA chips platform from Agilent Technologies and quantitative PCR apparatus from Applied Biosystems, which are already in place. A new Illumina Next Generation Sequence module for very high throughput DNA sequencing will be installed later this year in the second quarter.Since 2006, Imaxio offers its partners and customers a wide range of genomic services from sample preparation to bioinformatic analysis for use in genomic diagnostics and drug discovery and development. At this stage, Imaxio is proud to collaborate closely with top tier pharmaceutical, cosmetic and agro-food companies. In order to house this new platform, Imaxio has doubled its Genomics laboratory space in its Auvergne (Central France) site located in the Biopôle Clermont- Limagne, near Clermont-Ferrand. This investment has been supported by the Department of the Puy-de-Dôme and FEDER.
About Imaxio:
Imaxio is based in Lyons and Saint-Beauzire (near Clermont-Ferrand) in France and has 21 highly qualified employees. The company has programmes in the areas of oncology and infectious diseases, and aims to create new recombinant vaccines and new medicines (derived from its oncology screening platform) as well as new diagnostic and prognostic tools for common cancers.
Imaxio was formed by the merger in 2006 of Diagnogene and Avidis, which was created in 2000 as a spin-off from the UK Medical Research Council and the University of Cambridge. Imaxio has several awarded and pending patents for the technologies aXent™, OverExpress™, Diagnogene™ and PepAptamer™. Imaxio has recently acquired the company Axcell Biotechnologies which markets the vaccine Spirolept™ to prevent human leptospirosis... [PDF] Imaxio's Press Release (French + English) -
Imaxio is based in Lyons and Saint-Beauzire (near Clermont-Ferrand) in France and has 21 highly qualified employees. The company has programmes in the areas of oncology and infectious diseases, and aims to create new recombinant vaccines and new medicines (derived from its oncology screening platform) as well as new diagnostic and prognostic tools for common cancers.
Imaxio was formed by the merger in 2006 of Diagnogene and Avidis, which was created in 2000 as a spin-off from the UK Medical Research Council and the University of Cambridge. Imaxio has several awarded and pending patents for the technologies aXent™, OverExpress™, Diagnogene™ and PepAptamer™. Imaxio has recently acquired the company Axcell Biotechnologies which markets the vaccine Spirolept™ to prevent human leptospirosis... [PDF] Imaxio's Press Release (French + English) -
